New Pharmacyclics data could move Imbruvica to front-line
This article was originally published in Scrip
Executive Summary
Pharmacyclics reported just before the US stock market closed on 16 March that an independent data monitoring committee (IDMC) unanimously recommended that the Phase III HELIOS clinical trial in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) be unblinded due to a significant treatment benefit in the Imbruvica (ibrutinib) arm of the study.